More progress in Alzheimer's as anti-tau vaccine steps forward

As scientists and investors in Alzheimer’s digest the significance of the latest positive results from Biogen (Nasdaq: BIIB) and Eisai’s (TYO: 4523) program, more companies are getting back into the ring.

After decades of often high-profile research failures, many big drugmakers have  stepped away from investing in Alzheimer’s research in recent years.

However, as the  latest clinical update for the amyloid beta-clearing antibody lecanemab shows, to the highest standard of clinical proof yet, that there is a way to alter the course of the disease.